Prescribing Information [External link]
WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.
For more information on WELIREG visit the product page:
This section of the website contains promotional information intended for UK Healthcare Professionals only. If you are not a UK healthcare professional, please click here.
GB‑NON‑10777 | Date of Preparation: January 2025
This section of MSD Connect is an online portal containing promotional information about MSD pharmaceutical products, therapy area materials and professional resources and is intended for UK Healthcare Professionals.
To contact us please telephone 0208 154 8000 or email medicalinformationuk@msd.com | Privacy Policy | Terms of Use
GB-NON-10696 | Date of Preparation: January 2025
Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom.
Registered in England No. 233687 Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000)
As part of the implementation of the Windsor Framework, from January 1st 2025, all medicines approved by UK authorities will be available across the United Kingdom, including Northern Ireland. Therefore, for medicines on this website that currently have separate prescribing information links for Great Britain (GB) and Northern Ireland (NI), both links will now direct to a single, UK-wide prescribing information for that medicine.
GB-NON-10797 | Date of Preparation: January 2025